Cushing’s Syndrome and Acromegaly Treatment Market
Cushing’s Syndrome and Acromegaly Treatment Market By Drug Type (Cushing’s Syndrome Treatment and Acromegaly Treatment) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region - Global Market Report (2024 to 2034)
Analysis of Cushing’s Syndrome and Acromegaly Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Cushing’s Syndrome and Acromegaly Treatment Market Outlook (2024 to 2034)
The global Cushing's syndrome and acromegaly treatment market is projected to reach a value of US$ 14,630.0 million by 2034, with a CAGR of 9.3% until 2034. This growth is driven by the increasing prevalence of the syndrome, screening rates, awareness, and healthcare infrastructure development. The market is estimated to be valued at US$ 3,831.7 million in 2024.
Pituitary adenoma and multiple endocrine neoplasia are common causes of Cushing's syndrome, which is characterized by high blood pressure, abdominal obesity, redness, fatty lumps, weak muscles, acne, and brittle skin. The treatment alternatives for this condition have propelled the market worldwide.
Key Market Growth Drivers
- The market for Cushing's syndrome care is driven by a variety of causes, including the increasing frequency of acromegaly, the rise in hormonal illnesses, the increase in scientific trials, and the expanding public awareness of acromegaly.
- Pre-atherosclerotic and atherosclerotic lesions increase during prolonged coronary artery disease (CAD) remission. Visceral obesity and insulin resistance are strongly linked to carotid vascular damage in CD patients, suggesting they significantly contribute to vascular damage development and maintenance.
- Treatment for acromegaly and Cushing's disease is becoming more popular because of advancements in imaging, such as the introduction of computed tomography and magnetic resonance imaging.
- Cushing's syndrome and acromegaly recurrence rates following surgery, together with the need for non-invasive therapy, are driving a significant uptake of pharmacological treatment for both conditions.
Technological advancements could significantly boost the market for treatments for acromegaly and Cushing's syndrome, driven by the development of focused pharmacological therapies with minimal adverse effects. This growth is expected to strengthen the Cushing’s syndrome and acromegaly treatment market.
|Estimated Market Value (2024E)
|US$ 3,831.7 million
|Forecasted Market Value (2034F)
|US$ 14,630.0 million
|Global Market Growth Rate (2024 to 2034)
|Cushing’s Syndrome Treatment Segment Growth Rate (2024 to 2034)
|Hospital Pharmacies Segment Growth Rate (2024 to 2034)
|North America Market Share (2024)
|Latin America Market Share (2024)
|Key Companies Profiled
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Factors are Driving the Cushing’s Syndrome and Acromegaly Treatment Market?
“Technological Advancements in Healthcare Infrastructure”
Mood swings, elevated blood pressure, and weight gain mark an uncommon hormonal condition called Cushing's syndrome. Simultaneously, acromegaly is a growth hormone-related hormonal condition that causes enlargement of the hands, feet, face, and joints and joint discomfort. The market for treatments for Cushing's syndrome and amyotrophic liver disease is anticipated to expand significantly over the next several years as a result of these disorders' rising incidence.
Cushing's syndrome and acromegaly can be treated with a variety of techniques, including radiation therapy, surgery, and medicine. For these diseases, surgery is frequently the recommended course of action since it can provide a more long-lasting resolution. Medication is usually used to balance hormone levels and manage symptoms; radiation therapy is occasionally utilized as a supplementary therapeutic option. The medication contains symptoms and controls hormone levels. The treatment market has grown due to increased diagnosis, medical technology, and research advancements.
“Growing Inactive Lifestyles Skyrockets Demand for Cushing’s Syndrome and Acromegaly Treatment Market”
Cushing's syndrome is a condition that significantly reduces a patient's quality of life. It affects their physical, emotional, and mental well-being, and even after long-term and effective treatment, the impairment seems to persist. The cortisol-lowering drug sector is being driven by the diagnosis of Cushing's syndrome in older people and millennials who have limited mobility in their work lives.
The complex system of Cushing's syndrome impairs the patient's quality of life, considering both psychological and physical characteristics. Therefore, assessing the health-related quality of life of these patients is essential, and many criteria and surveys have been developed for this purpose. An active and healthy lifestyle can aid in the patient's recovery from illness and expand the market for cortisol-lowering drugs.
Which Factors Present Challenges to the Cushing’s Syndrome and Acromegaly Treatment Market Growth?
“Concerns over Somatostatin Analogs for Acromegaly Hinders the Cushing’s Syndrome Cure Advancements”
A notable obstacle in the Cushing's syndrome and acromegaly treatment market is the exorbitant expense of therapy, rendering it expensive for a considerable segment of the populace.
Increased awareness, prevalence, and infrastructural development are projected to drive significant growth in the global treatment market for Cushing's syndrome and acromegaly. The market's potential for expansion still needs to be constrained by the need to enhance pricy treatments in underdeveloped nations.
The issue is further exacerbated by the fact that many developing nations require more knowledge of these problems. Furthermore, the requirement for suitable infrastructure, equipment, and qualified healthcare personnel severely limits the market's expansion.
The market's overall development is hampered by these issues, which make it difficult for people with Cushing's syndrome and acromegaly to receive appropriate therapy.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
North America's market for Cushing's syndrome and acromegaly treatment is projected to expand at an astounding 9.6% annual growth rate through 2034. The main factor propelling development is the rising demand in critical international markets, including the United States and Canada, for drugs that decrease cortisol levels. By 2024, it is expected that acromegaly pharmaceuticals will make up 83.1% of the United States market.
Meanwhile, it is anticipated that by 2034, the Latin American market for hypopituitarism therapy will expand at a 6.8% CAGR. Brazil is expected to hold the top spot in the Latin American Cushing's syndrome management market in 2024 with a 56.4% market share.
Why is the United States Dominating the Global Cushing’s Syndrome and Acromegaly Treatment Market?
“Cortisol-lowering Medications Drives the United States Cushing's Syndrome Cure Industry”
|Market Value in 2024
|US$ 1,783 million
|CAGR (2024 to 2034)
It is anticipated that in 2024, the United States market for Cushing's syndrome management will reach a value of US$ 1,783 million, owing to significant growth in demand. Furthermore, the market is expected to register a CAGR of 9.6%, resulting in a market size of US$ 4,452 million by 2034.
Technology is creating enormous potential for growth in the Cushing's syndrome and acromegaly therapeutic goods industries. The use of Cushing's syndrome and acromegaly treatment items is anticipated to rise in the United States with the advent of tailored medication therapy, which successfully treats the illness with few side effects.
The development of Cushing's syndrome and acromegaly therapeutic applications in the United States is anticipated to be significantly aided by the assistance that various governments provide for orphan illnesses and imaging. In the upcoming years, these elements will support the need for Cushing's syndrome and acromegaly therapy solutions due to the increasing prevalence of these disorders.
Why is Brazil Considered an Important Market in the Cushing’s Syndrome and Acromegaly Treatment Industry?
“Cortisol Reduction Medications and Hyperpituitarism Therapy Drives Brazilian Healthcare Industry”
|Market Value in 2034
|US$ 316 million
|CAGR (2024 to 2034)
The market in Brazil is expected to proliferate, reaching a projected value of US$ 316 million by 2034. Latin America's market has been expanding gradually in recent years, with Brazil predicted to have a sizable share of 56.4% in 2024. The market is anticipated to grow at a CAGR of 6.9% from 2024 to 2034. The excessive use of growth hormone therapy and the growing acceptability of cortisol-lowering drugs have been the leading causes of this increase.
The demand for Cushing's syndrome and acromegaly in Latin America has surged, with Brazil and Chile being the most affected countries. In collaboration with local and international organizations, the Brazilian government is promoting public awareness and introducing new treatments for growth hormone receptor antagonists.
Cushing's syndrome is a hormonal disorder resulting from prolonged exposure to high cortisol levels, causing weight gain, muscle weakness, and depression. Acromegaly is a rare but severe hormonal disorder resulting from excessive growth hormone production by the pituitary gland, causing enlarged hands and feet, facial changes, and joint pain.
Growth hormone, which the pituitary gland generates, controls a child's growth and influences an adult and child's metabolism of fat, sugar, and protein. Overproduction of growth hormone can result in adult acromegaly and gigantism in teenagers. Growth hormone receptor antagonists work by attaching to these receptors and preventing them from functioning, offering a novel treatment option for amenorrhea and protection against other hormone-related disorders.
The Brazilian government's endeavor to enhance public knowledge of Cushing's syndrome and implement novel growth hormone receptor antagonist therapies is noteworthy in facilitating the health and overall quality of life for those impacted by these conditions throughout Latin America.
The therapy for Cushing's syndrome is expected to account for 57.6% of the market in 2024. Furthermore, a significant 42.4% of the market is expected to go toward acromegaly therapies, which will stabilize and diversify the industry's resources.
Furthermore, depending on the distribution channel, the hospital pharmacy sector is expected to hold a sizable part of 57.5% of the Cushing’s syndrome and acromegaly therapy market in 2024. In addition, it is projected that by 2034, retail pharmacies will hold a substantial 30.0% market share.
Why Cushing’s syndrome Treatment Market Experiences a Surge in Demand?
“Use of Excessive Growth Hormone Treatment for Cushing's Syndrome”
|Segment Share in 2024
The Cushing's syndrome treatment industry dominates the global market in terms of drug type, holding a significant 57.6% market share in 2024. In addition, there is a growing demand for Cushing's syndrome management solutions in the Somatostatin analogs for the acromegaly industry, with an estimated consumption value expected to reach US$ 3,463.4 million by 2024.
Cushing's syndrome is a condition characterized by a decrease in steroid use, requiring surgery, radiation, and medication. It is treated with glucocorticoid drugs like prednisone for autoimmune conditions. However, regular therapy can lead to exogenous Cushing syndrome, causing new problems. The high-dose dexamethasone suppression test is used to identify the cause of Cushing’s syndrome, distinguishing between a tumour in another body part and a pituitary adenoma. The global Cushing's syndrome management market is growing due to differences in therapies and advancements in healthcare systems and technology.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
The medical industry is witnessing a remarkable surge in the demand for primary treatments for Cushing's syndrome and acromegaly. Key players in this field are investing heavily in research and development to diversify their product range. They are establishing state-of-the-art manufacturing facilities and forging strategic alliances with small or mid-sized competitors to expand their market reach.
Significant companies are devoting a large portion of their resources to research and development to stay ahead of the competition. These efforts foster creativity and aid in the creation of cutting-edge products. In addition, they are using a range of marketing techniques, including partnerships, mergers, acquisitions, and the introduction of new products, to increase their worldwide market share and keep a competitive advantage.
- In September 2023, The FDA released draft guidance for developing drugs for endogenous Cushing's syndrome treatment, advising sponsors on clinical trial designs for adults without surgery or curative outcomes.
- In June 2020, Chiasma Inc. received FDA approval for its revolutionary drug MYCAPSSA, containing Octreotide, the first oral somatostatin analog. This drug has the potential to revolutionize the treatment of acromegaly, a rare hormonal disorder.
Segmentation of Cushing’s Syndrome and Acromegaly Treatment Market
By Drug Type:
- Cushing’s Syndrome Treatment
- Acromegaly Treatment
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Latin America
- East Asia
- South Asia & Oceania
- Middle East & Africa
- FAQs -
What was the value of the Cushing’s Syndrome and Acromegaly Treatment Market in 2019?
The global Cushing’s syndrome and acromegaly treatment market was worth US$ 3,831.7 million in 2019.
What is the sales outlook for Cushing’s Syndrome and Acromegaly Treatment in 2024?
The sales outlook for Cushing’s syndrome and acromegaly treatment is likely to be valued at US$ 6,008.8 million in 2024.
What is the Demand Forecast for Cushing’s Syndrome and Acromegaly Treatment?
The demand for Cushing’s syndrome and acromegaly treatment is projected to reach a market value of US$ 14,630.0 million by 2034.
What is the Growth Projection for the Cushing’s Syndrome and Acromegaly Treatment Market?
The adoption of Cushing’s syndrome and acromegaly treatment is projected to rise at a CAGR of 9.3% through 2034.
At What Rate is the North American Market Predicted to Grow?
The North American market for Cushing’s syndrome and acromegaly treatment is forecasted to expand at a CAGR of 9.6% through 2034.